在卵巢癌化疗试验中，单药聚乙二醇化脂质体阿霉素用作对照臂所面临的严重伦理困境。 - Suppr | 超能文献

Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials.

作者信息

Markman Maurie

出版信息

J Clin Oncol. 2010 Jul 1;28(19):e319-20; author reply e321-2. doi: 10.1200/JCO.2010.28.9934. Epub 2010 Jun 1.

DOI:10.1200/JCO.2010.28.9934

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials.在卵巢癌化疗试验中，单药聚乙二醇化脂质体阿霉素用作对照臂所面临的严重伦理困境。

J Clin Oncol. 2010 Jul 1;28(19):e319-20; author reply e321-2. doi: 10.1200/JCO.2010.28.9934. Epub 2010 Jun 1.

2

[Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].聚乙二醇化脂质体阿霉素与卡铂联合紫杉醇与卡铂治疗铂敏感型卵巢癌晚期复发患者的比较

Klin Onkol. 2011;24(6):475-6.

3

Role of pegylated liposomal doxorubicin in ovarian cancer.聚乙二醇化脂质体阿霉素在卵巢癌中的作用。

Gynecol Oncol. 2005 Jan;96(1):10-8. doi: 10.1016/j.ygyno.2004.09.046.

4

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.与卡铂-紫杉醇联合治疗相比，卡铂-聚乙二醇脂质体阿霉素降低了过敏反应：GCIG CALYPSO 复发性卵巢癌试验的分析。

Gynecol Oncol. 2011 Aug;122(2):226-32. doi: 10.1016/j.ygyno.2011.04.019. Epub 2011 May 14.

5

What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?在乳腺癌治疗中，聚乙二醇化脂质体阿霉素的正确给药方式是什么？

J Clin Oncol. 2010 Apr 20;28(12):e193-4; author reply e195-6. doi: 10.1200/JCO.2009.26.8052. Epub 2010 Mar 1.

6

Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer.曲贝替定加聚乙二醇化脂质体阿霉素：卵巢癌治疗选择的回归。

Future Oncol. 2013 Dec;9(12 Suppl):1. doi: 10.2217/fon.13.203.

7

[Absence of cutaneous complications following extravasation of pegylated liposomal doxorubicin].[聚乙二醇化脂质体阿霉素外渗后无皮肤并发症]

Presse Med. 2003 Jun 28;32(23):1077.

8

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.聚乙二醇化脂质体阿霉素（PLD）联合卡铂治疗6至12个月内复发的卵巢癌患者的疗效：一项II期研究。

Gynecol Oncol. 2009 Sep;114(3):410-4. doi: 10.1016/j.ygyno.2009.04.037. Epub 2009 Jun 10.

9

Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.聚乙二醇化脂质体阿霉素与卡铂治疗铂敏感和部分铂敏感转移性卵巢癌患者的II期研究。

Int J Gynecol Cancer. 2009 Aug;19(6):1137-41. doi: 10.1111/IGC.0b013e3181a8b938.

10

Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.复发性卵巢癌患者报告结局：多柔比星脂质体注射液联合 trabectedin 与多柔比星脂质体注射液单药治疗随机 III 期研究结果。

Gynecol Oncol. 2012 Oct;127(1):161-7. doi: 10.1016/j.ygyno.2012.06.034. Epub 2012 Jul 2.

引用本文的文献

1

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.随机 III 期临床试验比较聚乙二醇脂质体阿霉素（PLD）50mg/m²与 40mg/m²在铂耐药和铂抵抗性卵巢癌患者中的疗效：JGOG 3018 试验。

J Gynecol Oncol. 2021 Jan;32(1):e9. doi: 10.3802/jgo.2021.32.e9. Epub 2020 Nov 10.

2

2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy.用于确定安全有效最佳剂量的二维（2D）TEQR设计。

Contemp Clin Trials Commun. 2019 Oct 12;16:100461. doi: 10.1016/j.conctc.2019.100461. eCollection 2019 Dec.

3

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.聚乙二醇化脂质体阿霉素用于复发性上皮性卵巢癌

Cochrane Database Syst Rev. 2013 Jul 9;2013(7):CD006910. doi: 10.1002/14651858.CD006910.pub2.